New Research Poster Presentation 3.6: The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6-12 Years of Age with ADHD in a Double-Blind, Placebo-Controlled Trial

Thursday, October 29, 2009 12:30 PM

Ann Childress, M.D., Center for Psychiatry and Behavioral Medicine, Las Vegas, NV

Valerie Arnold, M.D., University of Tennessee, Memphis, TN

Ben Adeyi, M.S., Shire Pharmaceuticals Inc., Wayne, PA

Bryan Dirks, M.D., Shire Pharmaceuticals Inc., Wayne, PA

Thomas Babcock, D.O., Ph.D., Shire Pharmaceuticals Inc., Wayne, PA

Brian Scheckner, PharmD, Shire Pharmaceuticals Inc., Wayne, PA

Robert Lasser, M.D., Shire Pharmaceuticals Inc., Wayne, PA

Frank Lopez, M.D., Children's Developmental Center, Winter Park, FL

		56th Annual Meeting Tentative Program Schedule
		Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 3.6 The Effects of Lisdexamfetamine Dimesylate on Emotional Lability in Children 6-12 Years of Age with ADHD in a Double-Blind, Placebo-Controlled Trial